Search
Levmetamfetamine
go.drugbank.com/drugs/DB09571ApprovedLevomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalThe mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.
Lufotrelvir
go.drugbank.com/drugs/DB16514InvestigationalPF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728].
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394] … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Nicardipine
go.drugbank.com/drugs/DB00622ApprovedInvestigationalIt has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem] … It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects.
alpha-Amyl cinnamaldehyde
go.drugbank.com/drugs/DB14175Approvedalpha-Amyl cinnamaldehyde has a jasmine-like odor and is a widely used synthetic fragrance & suspected allergen. It is used in allergenic testing.
CRx-401
go.drugbank.com/drugs/DB05775Experimentalhas proven to be well tolerated in clinical trials. … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose
TG-100801
go.drugbank.com/drugs/DB05075InvestigationalIt is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological